HCP Targeting for Pharma and Medtech: Reaching Doctors via Programmatic and Medical Apps

This post is for brand managers, digital leads and agency planners at pharma and medtech companies in India who have been asked to "reach doctors online" and need a defensible plan. It compares the main ways to reach healthcare professionals (HCPs), explains what each can and cannot verify, places them against the Uniform Code for Pharmaceutical Marketing Practices 2024, and sets out how to measure the result.

It is a framework, not legal advice. Anything that promotes a prescription medicine or a regulated device needs review by your medical, legal and regulatory team before it goes live. We have not seen reliable public data on HCP media inventory or prices in India, so the sections below tell you what to ask and how to test, not what to expect.

Reaching doctors is a different problem from reaching patients. The audience is small, the claims allowed are narrow, and the risk of an advertisement reaching the lay public is a regulatory issue as well as a waste of budget. Our broader pharma marketing guide covers strategy; this post is only about targeting.

The regulatory frame, briefly

The UCPMP 2024 was issued by the Department of Pharmaceuticals on 12 March 2024. Points that bear on HCP media buying, from the code's text:

• Clause 1.2: promotion must be consistent with the drug's marketing approval, and a drug must not be promoted before approval.
• Clause 3.2: promotional material meant to give prescribers information to decide on a prescription must carry minimum information, including the generic name beside the brand name, dosage and method of use, adverse reactions, warnings and contraindications, and a statement that more information is available on request with a date.
• Clause 3.3: promotional material must not be designed to disguise its real nature, and paid material in journals must not resemble editorial matter.
• Clause 3.6: the names or photographs of healthcare professionals must not be used in promotional material. This matters for KOL-led digital content; see our note on KOLs.
• Clause 4.5: third parties acting on behalf of pharmaceutical companies should know the code. Your agency and your programmatic vendor are inside the compliance perimeter.
• Clause 14.2: the provisions apply, unless exempted or modified, to medical devices and the companies that make or sell them. Medtech teams should not assume the code is irrelevant.

Separately, the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954 restricts advertising for remedies claimed to treat conditions in its schedule, and carves out certain communications sent confidentially to registered medical practitioners. Do not read that carve-out as permission for any media that happens to reach doctors. Ask counsel how it applies to each format and product.

The practical consequence: an HCP campaign must be able to show that the intended audience was professionals, and that the creative and landing page carry what the code requires.

The inventory options, compared

Many plans mix three of these. The mistake to avoid is treating "targeted at doctors" as a property of the channel. It is a property of the evidence a vendor can show you.

Vendor questions that expose weak HCP claims

Put these in the brief and ask for written answers.

1. How is an HCP verified? Against a state or national register, by medical council number, by institutional email, or by self-declaration? The National Medical Commission maintains the register of medical practitioners, and a vendor who verifies against registries should be able to say which.
2. How often is verification refreshed? Registrations lapse and people move.
3. What share of delivered impressions went to verified HCPs? Ask for log-level evidence or an independent verification report, not a platform estimate.
4. What is the deduplicated reach? Impressions repeated to the same 500 doctors are not 5,000 doctors reached. Ask for unique reach and frequency by specialty.
5. Can you exclude and report on lay-audience exposure? Particularly on open-web programmatic and on social placements.
6. Where does the data come from, and under what consent? Under the Digital Personal Data Protection Act, 2023, personal data used for targeting needs a lawful basis. See the data protection framework page for the Act and Rules, and confirm commencement dates with counsel because the Rules phase in.
7. Which specialties and cities are covered? A strong cardiology segment in Mumbai says little about nephrology in Coimbatore.
8. What happens to the ad when the user cannot be identified? The default should be no ad, not a general audience.

If a vendor cannot answer five of these eight, treat the "HCP" label as a marketing term.

Creative and landing page controls

• Gate prescribing information. Put clause 3.2 content on a page that is clearly addressed to prescribers, and consider a registration-number check before showing product claims. A single "I am a doctor" button is a weak control.
• Keep ad copy within approved claims. Maintain a claims library with reference citations. Every claim in an ad must trace to an approved source.
• Label the nature of the content. Sponsored content in an editorial layout must be recognisable as promotion.
• Do not use real HCPs' names or photos in promotional material, given clause 3.6.
• Keep the approval record. Store the approved version, approval date and reviewers for every creative, as agencies are inside the compliance perimeter under clause 4.5.

Measurement designs that fit a small audience

An HCP audience may be a few thousand people, so click-through rates on their own mislead. Use layers:

1. Delivery quality. Unique verified reach, frequency, viewability and the lay-exposure report from the vendor, audited by you.
2. Engagement depth. Time on the prescriber page, detail-aid views, requests for a representative visit or a sample (where allowed), CME sign-ups. These are closer to intent than clicks.
3. Field-force linkage. Pass opt-in digital engagement to the CRM so the representative sees it before the visit. Measure whether visits preceded by digital contact lead to different next steps than visits without.
4. Territory holdout. Choose matched territories, run the campaign in some and not in others for a fixed period, and compare change in the outcome you care about. Pre-agree the outcome: prescriber trial, sample requests, or secondary sales where you have the data.
5. HCP panel survey. For awareness, run a short survey before and after with a sample of the target specialty, and keep the same questions.

A hypothetical example, with invented numbers. A medtech company runs a device-awareness campaign for orthopaedic surgeons in 8 matched territories and holds out 8 others. It records, per territory, the number of surgeons who requested a product demonstration in the ten weeks before and during the campaign. The relevant output is the difference in change between the two groups, with the range across territories, not the total requests in the exposed group.

Governance workflow

• Intake: brand team states product, indication, audience specialty and cities.
• Medical-legal-regulatory review of creative, targeting rationale and landing page before booking media.
• Vendor due diligence using the eight questions above, with answers on file.
• Pre-flight checks: exclusion lists, geographic settings, frequency caps, and a test of how the ad appears to a non-HCP user.
• In-flight monitoring of placements weekly; pause if lay exposure appears.
• Post-campaign record of reach, spend, complaints and approvals, held for audit.

For patient-facing promotion of non-prescription products, the rules differ and platform policies apply; check medical advertising rules and the platform's pharma policy before assuming HCP methods carry over. If you also run LinkedIn for hospital administrators, see our LinkedIn management service.

Where to start

1. List the three specialties and ten cities that matter, and the one outcome you will measure.
2. Request written answers to the eight vendor questions from two or three candidates, including at least one first-party doctor network.
3. Have regulatory review the prescriber landing page before any media is booked.
4. Run a small pilot (one specialty, one region) with a matched-territory comparison.
5. Decide scale-up only after the delivery audit shows who actually saw the ads.

Our pharmaceutical industry page outlines how we approach compliant digital programmes, and the pharma digital marketing guide covers the surrounding activities.